Results 321 to 330 of about 364,595 (399)

Timely post-discharge medication reviews to Improve Continuity-the Transitions Of Care stewardship (TIC TOC) study in rural and regional Australia: a parallel-group randomised controlled trial study protocol. [PDF]

BMJ Open
Penm J, Yeung K, Moles RJ, Criddle D, Elliott RA, Rigby D, Shakib S, Sanfilippo FM, Carter SR, Budgeon C, Nguyen K, Yates P, Phillips K, Yik J, McMillan F, Hawthorne D, Fleming C, Packer A, Krogh L, Poon SK, Chambers B, Liu S, Emadi F, Chen J, Englezos K, Ratnanayagam G, Penm M, Hawthorne A, Khlentzos A, Khlentzos J, Angley M.   +30 more
europepmc   +1 more source

Beyond cytotoxic T cells: reprogrammed regulatory T cells help facilitate response to dual checkpoint blockade

Molecular Oncology, EarlyView.
Rolig, Peng, and colleagues have shed new light on how dual blockade of PD1 and LAG3 enhances antitumor immunity. They found that response to immunotherapy with anti‐PD1 + anti‐LAG3 was associated with reprogramming of canonically suppressive CD4+ regulatory T cells to an inflammatory state.
Tullia C. Bruno, Anthony R. Cillo
wiley   +1 more source

Clinical Outcomes of Pharmacist Involvement in Cardiac Arrest and Trauma Resuscitations: A Scoping Review. [PDF]

Pharmacy (Basel)
Patel H, Wee M, Tejani AM, Lau A.
europepmc   +1 more source

Integrative miRNOMe profiling reveals the miR‐195‐5p–CHEK1 axis and its impact on luminal breast cancer outcomes

Molecular Oncology, EarlyView.
In luminal (ER+) breast carcinoma (BC), miRNA profiling identified miR‐195‐5p as a key regulator of proliferation that targets CHEK1, CDC25A, and CCNE1. High CHEK1 expression correlates with worse relapse‐free survival after chemotherapy, especially in patients with luminal A subtype.
Veronika Boušková, Marie Ehrlichová, Alžběta Spálenková, Ivona Krus, Simona Šůsová, Viktor Hlaváč, Vlasta Němcová, Renata Koževnikovová, Markéta Trnková, David Vrána, Jiří Gatěk, Kateřina Kopečková, Marcela Mrhalová, Soňa Měšťáková, Pavel Souček   +14 more
wiley   +1 more source

Community-Originated Research to Identify Access Gaps in Over-the-Counter Naloxone Availability in Connecticut Pharmacies. [PDF]

Harm Reduct J
Hill K, Canning P, Canning Z, Breen C, Evans L, Jenkins M, Nickel M, Plourd K, Heimer R.   +8 more
europepmc   +1 more source

Association of high‐dose radioactive iodine therapy with PPM1D‐mutated clonal hematopoiesis in older individuals

Molecular Oncology, EarlyView.
In thyroid cancer patients, high‐dose (≥7.4 GBq) radioactive iodine therapy (RAIT) was associated with a higher prevalence of clonal hematopoiesis (variant allele frequency >2%) in individuals aged ≥50 years (OR = 2.44). In silico analyses showed that truncating PPM1D mutations conferred a selective advantage under these conditions.
Jaeryuk Kim, Sungwoo Bae, Jaeyong Choi, Sun‐Wha Im, Bukyoung Cha, Gyeongseo Jung, Sun Wook Cho, Eul‐Ju Seo, Young Ah Lee, Jin Chul Paeng, Young Joo Park, Jong‐Il Kim   +11 more
wiley   +1 more source

Correlation of HbA1c and Continuous Glucose Monitor Time in Range. [PDF]

J Pharm Technol
DePasquale H, DeLucenay A, Ahmed-Sarwar N.   +2 more
europepmc   +1 more source

Development and Validation of Predictive Models for Non-Adherence to Antihypertensive Medication. [PDF]

Medicina (Kaunas)
Marineci CD, Valeanu A, Chiriță C, Negreș S, Stoicescu C, Chioncel V.   +5 more
europepmc   +1 more source

Caring for communities: A 4-year pharmacy partnership focused on diabetes and cardiovascular health. [PDF]

J Manag Care Spec Pharm
Nuffer W, Thompson A, Stenhoff K, Bjork M.   +3 more
europepmc   +1 more source

The Clinical Pharmacist-Led Medication Review Service at the Surgical Department: A Feasibility Study. [PDF]

Scand J Caring Sci
Christiansen M, Joensen N, Jacobsen R.
europepmc   +1 more source